Division of Hematopathology, Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN, US.
Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, US.
Am J Clin Pathol. 2024 Jun 3;161(6):609-624. doi: 10.1093/ajcp/aqad186.
VEXAS syndrome is an adult-onset autoinflammatory disease caused by a somatic pathogenic mutation in the UBA1 (ubiquitin-like modifier activating enzyme 1) gene. Patients present with rheumatologic manifestations and cytopenias and may have an increased predisposition to myelodysplastic syndrome (MDS) and plasma cell neoplasms. Prior studies have reported on the peripheral blood and bone marrow findings in patients with VEXAS syndrome. Due to the protean clinical presentation and lack of specificity of morphologic features (eg, vacuoles in early erythroid and granulocytic precursors), an optimal screening methodology to identify these patients in a timely fashion is desirable.
To further evaluate and describe the salient diagnostic morphologic features in VEXAS syndrome, we carried out a comprehensive study of the largest single-institution cohort to date. Diagnostic and follow-up bone marrow biopsy specimens from 52 male patients with molecularly identified VEXAS syndrome underwent central review.
Cytopenias were common in all cases, primarily macrocytic anemia, monocytopenia, and thrombocytopenia. Bone marrow aspirate and biopsy were often hypercellular, with an increased myeloid/erythroid ratio, granulocytic hyperplasia with left shift, erythroid left shift, and megakaryocyte hyperplasia, which exhibited a range of striking morphologic findings. Distinctly vacuolated myeloid and erythroid precursors were seen in more than 95% of cases.
Our data reveal potential novel diagnostic features, such as a high incidence of monocytopenia and distinct patterns of atypical megakaryopoiesis, that appear different from dysmegakaryopoiesis typically associated with MDS. In our experience, those findings are suggestive of VEXAS, in the appropriate clinical context.
VEXAS 综合征是一种由 UBA1(泛素样修饰物激活酶 1)基因的体细胞致病性突变引起的成人发病的自身炎症性疾病。患者表现为风湿学表现和细胞减少症,并且可能有增加的骨髓增生异常综合征(MDS)和浆细胞瘤的倾向。先前的研究已经报道了 VEXAS 综合征患者的外周血和骨髓发现。由于临床表现多样且形态特征缺乏特异性(例如,早期红系和粒系前体细胞中的空泡),因此需要一种最佳的筛选方法来及时识别这些患者。
为了进一步评估和描述 VEXAS 综合征的显著诊断形态学特征,我们对迄今为止最大的单机构队列进行了全面研究。对 52 名经分子鉴定患有 VEXAS 综合征的男性患者的诊断和随访骨髓活检标本进行了中心审查。
所有病例均存在细胞减少症,主要为巨细胞性贫血、单核细胞减少症和血小板减少症。骨髓抽吸和活检通常为高细胞性,骨髓有核细胞与红细胞的比例增加,粒细胞增生伴有左移,红系左移,巨核细胞增生,并表现出一系列显著的形态学发现。超过 95%的病例中可见明显有空泡的髓系和红系前体细胞。
我们的数据揭示了一些潜在的新的诊断特征,例如单核细胞减少症的发生率较高和明显的非典型巨核细胞生成模式,这些特征与通常与 MDS 相关的非典型巨核细胞生成不同。根据我们的经验,这些发现提示可能是 VEXAS,在适当的临床背景下。